Protagonist Therapeutics, Inc. $PTGX Stock Holdings Reduced by Knott David M Jr

Knott David M Jr lowered its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 13.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 63,000 shares of the company’s stock after selling 10,000 shares during the quarter. Protagonist Therapeutics makes up 3.9% of Knott David M Jr’s portfolio, making the stock its 5th biggest position. Knott David M Jr’s holdings in Protagonist Therapeutics were worth $6,640,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of PTGX. Farther Finance Advisors LLC boosted its stake in shares of Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares in the last quarter. Greenline Wealth Management LLC bought a new position in Protagonist Therapeutics in the fourth quarter worth approximately $27,000. Osaic Holdings Inc. raised its stake in Protagonist Therapeutics by 79.5% in the second quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock worth $65,000 after buying an additional 525 shares in the last quarter. Hantz Financial Services Inc. lifted its holdings in Protagonist Therapeutics by 222.4% during the fourth quarter. Hantz Financial Services Inc. now owns 951 shares of the company’s stock worth $83,000 after buying an additional 656 shares during the period. Finally, Canton Hathaway LLC purchased a new stake in Protagonist Therapeutics during the fourth quarter worth $87,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Insider Transactions at Protagonist Therapeutics

In other news, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total value of $7,509,000.00. Following the completion of the sale, the chief executive officer owned 523,478 shares of the company’s stock, valued at $52,410,617.36. This trade represents a 12.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William D. Waddill sold 9,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total value of $1,061,460.00. Following the transaction, the director owned 7,825 shares in the company, valued at approximately $922,880.50. This trade represents a 53.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 161,130 shares of company stock valued at $16,355,220 in the last quarter. 5.19% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PTGX. Zacks Research upgraded Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. Weiss Ratings restated a “sell (d+)” rating on shares of Protagonist Therapeutics in a research note on Friday, May 15th. TD Cowen restated a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday, July 1st. Barclays raised their price objective on Protagonist Therapeutics from $119.00 to $151.00 and gave the company an “overweight” rating in a research report on Tuesday, July 14th. Finally, Truist Financial boosted their target price on shares of Protagonist Therapeutics from $121.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $123.00.

Protagonist Therapeutics Stock Down 0.0%

Shares of PTGX opened at $135.43 on Friday. The company has a market cap of $8.71 billion, a price-to-earnings ratio of -74.82 and a beta of 1.79. Protagonist Therapeutics, Inc. has a twelve month low of $50.49 and a twelve month high of $143.29. The company has a 50 day moving average of $116.11 and a two-hundred day moving average of $101.09.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.55. The business had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. On average, sell-side analysts expect that Protagonist Therapeutics, Inc. will post 3.69 EPS for the current year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.